Last $3.60 USD
Change Today -0.24 / -6.25%
Volume 577.0
RESX On Other Exchanges
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

restorgenex corp (RESX) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/23/13 - $14.00
52 Week Low
03/5/14 - $2.37
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for RESTORGENEX CORP (RESX)

Related News

No related news articles were found.

restorgenex corp (RESX) Related Businessweek News

No Related Businessweek News Found

restorgenex corp (RESX) Details

RestorGenex Corporation operates as a specialty biopharmaceutical company that focuses on developing products for dermatology, ophthalmology, and women’s health. Its product under development includes HYG-102, a soft estrogen for the treatment of aging skin fragility/thinning; HYG-440, a soft anti-androgen for the treatment of androgen excess, e.g. acne, male-pattern baldness, and hirsutism; and P529, a prescription dermatology compound used for the treatment of keloid scarring, psoriasis, atopic dermatitis, rosacea, actinic keratosis, Dupuytren’s disease, and the bullous blistering diseases. RestorGenex Corporation has Collaboration Agreement with Ferndale Pharma Group, Inc. for developing aging skin product. The company was formerly known as Stratus Media Group, Inc. and changed its name to RestorGenex Corporation in March 2014. RestorGenex Corporation is based in Los Angeles, California.

restorgenex corp (RESX) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

restorgenex corp (RESX) Key Developments

RestorGenex Corporation Reports Earnings Results for the Second Quarter Ended June 30, 2014

RestorGenex Corporation reported earnings results for the second quarter ended June 30, 2014. The company incurred a net loss of approximately $4.5 million or $0.35 per share for the quarter ended June 30, 2014, compared to net income of $2.3 million or $0.82 per share for the same period in 2013. The increase in the net loss was due primarily to $10.6 million in other income recognized in 2013 for non-cash gains on adjustments to the fair value of the company's previously owned derivative liability and extinguishment of that derivative liability combined with higher expenses in 2014 associated with the Company's research and development efforts to advance its technologies and products.

RestorGenex Appoints Mark Weinberg as Senior Vice President of Clinical Development

RestorGenex Corporation announced the appointment of Mark Weinberg MD, MBA as Senior Vice President of Clinical Development. Before joining RestorGenex, Dr. Weinberg served as Vice President, Global Clinical Science at Astellas Pharma Global Development. Prior to Astellas, he was Vice President, Medical Strategy and Medical Affairs at Lundbeck Inc. (formerly Ovation Pharmaceuticals). Previously, Dr. Weinberg held roles of increasing responsibility in clinical development at Takeda Global Research and Development and Abbott Laboratories.

Restorgenex Corporation Announces Management Changes

Restorgenex Corporation announced several management changes. The company has appointed Phillip B. Donenberg as its chief financial offer. Before RestorGenex, he served as BioSante Pharmaceuticals Inc.'s Senior Vice President of Finance from 2010 until June 19, 2013 and Chief Financial Officer and Secretary from 1998 until June 19, 2013 when BioSante merged with ANIP Acquisition Company, d/b/a ANI Pharmaceuticals Inc. In other developments, it has appointed Yael Schwartz, PhD as its Executive Vice President of Preclinical Development. Previously, Dr. Schwartz was president of RestorGenex's Canterbury/Hygeia wholly owned subsidiaries. In addition, the company announced that David Sherris, Ph.D.'s new title is Chief Scientific Officer of RestorGenex. Previously, Dr. Sherris was Chief Scientific Officer and President of RestorGenex's Paloma/VasculoMedics wholly owned subsidiaries. Jerold Rubinstein, former CEO and chair of the audit committee, resigned from the RestorGenex board of directors as part of the company's efforts to achieve a majority of independent directors in anticipation of an application to list the company's common stock on the NASDAQ Stock Market. Mr. Rubinstein will remain a senior advisor to the RestorGenex board of directors for at least the year 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RESX:US $3.60 USD -0.24

RESX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RESX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RESX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 646.4x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 536.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact RESTORGENEX CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at